MESALAMINE (mesalamine) by Viatris (2) is understood, but appears to be topical rather than systemic. Approved for mildly to moderately active ulcerative colitis, for the maintenance of remission of ulcerative colitis, ulcerative colitis. First approved in 2019.
Drug data last refreshed 18h ago
understood, but appears to be topical rather than systemic. Although the pathology of inflammatory bowel disease is uncertain, both prostaglandins and leukotrienes have been implicated as mediators of mucosal injury and inflammation.
Aminosalicylate
Worked on MESALAMINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)